BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) ...

BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) ...


BioCryst Pharmaceuticals, Inc. today announced that results from a study of galidesivir administered to Rhesus monkeys infected with Zika virus will be presented as a late-breaker oral presentation at IDWeek 2016 taking place in New Orleans October 26-30, 2016. The presentation titled "BCX4430, a Broad-Spectrum Adenosine Analog Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus," will be presented by James B. Whitney, PhD, Assistant Professor of Medicine, Harvard Medical School, and Principal Investigator in the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.



from Biotech News